The Biointelect management team individually have greater than 20 years’ experience and proven track records in small start-up ventures and multinational corporations.
We, therefore, uniquely understand our client’s needs. We have successfully managed business units or companies and navigated complex regulatory, clinical research, quality management, commercial, product launches and business partnering strategies.
Our consulting philosophy is to always offer a personalised and adaptable service. We take ownership of our projects seriously and strive for success as if we were part of your team.
Member of the Accelerate Commercialisation Expert Network and on the Steering Committee of PRISM and APPRISE.
Over 20 years commercial & scientific affairs experience in the biopharmaceutical industry.
As the first managing director of Sanofi Pasteur in Australia, Jennifer led the company’s growth from a start-up to its position today as a leading provider of vaccines. Served on the Board of Medicines Australia and founded the Medicines Australia Vaccine Industry Group, experience with WHO & IFPMA.
Extensive international & local network of industry, government, scientific and clinical experts across many therapeutic areas and healthcare sectors along with global experience in multiple new product launches and start-ups at all stages of development.
Graduated from UTS in Biomedicine, majoring in biochemistry and microbiology. Post graduate certificate in marketing. Australian Institute of Company Directors member.
Over 25 years of varied experience in the pharmaceutical industry – from the lab to senior management.
Extensive marketing and commercial experience with major companies GSK, Sanofi and Sigma Pharmaceuticals, as well as start-ups like Generic Health a subsidiary of Lupin Pharmaceuticals.
Wide experience across a number of therapeutic areas, including oncology, cardiovascular disease and diabetes.
Scientific Affairs Director
Over 20 years of experience in the diagnostics, biotechnology, medical device and pharmaceutical industry
Extensive employment experience with major companies Wyeth, Merck Sharp and Dohme, Novo Nordisk,
Janssen-Cilag and Roche Diagnostics; start-up ventures including Sanofi Pasteur and IBAH (the CRO now known as Omnicare) and Columna.
Managed in excess of 20 Phase I-IV clinical and health outcome projects locally and globally.
Joined Biointelect in 2016 as Director of Scientific Affairs.
SME for World Medical Device Organisation, Lecturer: Masters in Health Technology Innovation, Sydney University.
Head, Global Health Outcomes and Policy
David Grainger has forty years of experience in the pharmaceutical industry, spanning Australia, New Zealand, the United States and short assignments in Brussels and London.
He completed his life sciences studies at the University of Auckland with majors in haematology and transfusion science, management studies with the New Zealand Institute of Management and health economics at Monash University in Melbourne, Australia. David is the co-author of numerous publications on health economics and health outcomes research.
David’s industry experience includes a range of roles in sales, marketing, health outcomes research and corporate affairs. This includes 10 years as the director of corporate affairs and market access in Eli Lilly’s Australian affiliate, responsible for all health outcomes research, reimbursement dossier development & pricing functions as well as the corporate affairs functions of government relations, advocacy & communications.
More recently David held a senior role in Lilly’s international public policy group, responsible for developing and supporting the company’s external health care policy positions related to Health Technology Assessment (HTA). David also engaged extensively with governments and thought leaders in a range of markets on policy issues related to universal health coverage, formulary management, HTA, pricing and regulatory affairs.
David has had significant involvement with industry association policy efforts and for six years chaired the HTA Task Force for PhRMA International. He is a member of the Board of Directors of Health Technology Assessment International, a professional society dedicated to HTA. David is also a member of the Policy Research Advisory Committee for the Office of Health Economics in London and a casual lecturer in the Masters of Pharmaceutical Medicine program at the University of New South Wales in Sydney.
Ross Linsley is a proven leader, facilitator and strategist with 25+ years’ experience and expertise in the Pharmaceutical Industry and Public and Private Healthcare across the Asia Pacific Region. He also has broad experience covering Key Account Management, Commercial Excellence, Marketing, Sales and Business Development at a senior level with companies including Abbvie, Abbott, Merck Serono, AstraZeneca and Aventis.
Ross was Area Commercial Director for Japan and Asia Pacific (JAPAC) for the hepatitis C franchise where he was responsible for developing commercial strategy, defining the long range focus and alignment with the affiliates. Ross therefore brings an existing network in infectious diseases and insight to optimize private market strategy for the JAPAC region.
He is an innovative, culturally sensitive and collaborative consultant, whose approach is in building a better understand of the environment, risks and opportunities; and to develop clear strategies to improve business performance. Ross is joining the Biointelect team to help develop their Asia Pacific business.
Pierre Marin has over 17 years of management experience in the Pharma industry from finance to strategy, operations and General Management at local, regional and global levels. In his last management role, he was heading Sanofi Vaccines Business in Asia based in Singapore before becoming personal advisor to the newly appointed Sanofi Vaccines CEO for 2 years. Whilst in Asia, Pierre had full P&L responsibility for 15 countries. 350+ people and 150ME sales.
Pierre began consulting to bring innovative strategic thinking and change management capabilities to companies willing to convert change & growth imperatives into development opportunities for their people and their businesses. He also brings 4 years’ experience as an independent consultant in the field of strategy definition and execution, operational turnaround, change management and executive coaching.
His current clients include big pharma, biotech’s, investors & NGOs for whom he’s been leading. He also has experience dealing with companywide business cases from strategic framing to workshops facilitation to financial modeling to Board Level presentation and recommendations, business opportunities assessments from ground work to strategic recommendations along with Execution strategies for key projects such as new product launches, M&A, integration. He graduated from HEC Management School in Paris. He is an alumni of INSEAD and became and ICF certified coach in 2011 (RCS, London).
Pierre joined Biointelect in 2017 to establish their European office and is based in Lyon, France
Carlos Espinal has long-term experience in tropical diseases, epidemiology, vaccinology and public health. One year (October 2015-16) as the Director of the Global Health Consortium, College of Public Health, Florida International University, Miami, Florida. One year as the Scientific Adviser of the Americas Health Foundation, USA. Over 20 years of experience in the vaccine pharmaceutical sector(Biolhener, GSK, Sanofi pasteur) as country, sub-regional and Regional Medical and Public Health Director.
MBA from the Australian Graduate School of Management at University of New South Wales Business School, Master Degree in Engineering for Health and Drugs (Biotechnology, Health and Management) from the University Joseph Fourier in Grenoble, France and a Master Degree in Entrepreneurship in Life Sciences & Technologies from the University Paris-Sud XI, France.
10+ years of international experience in the biopharmaceutical and medical device industries across US, Europe and Australia.
Expertise and a successful track record in growth strategies, implementation and innovation in healthcare across new product & service development and commercialisation, corporate and business development (acquisition, license-in, partnership) and operational and general management (including sales & marketing, full company P&L ownership).
Also the inventor of several granted patents currently used in various commercial ventures.
Joined Biointelect in January 2017 as a Consultant Manager.
As a Registered Nurse, Jane’s experience, knowledge and professional networks within the health sector is diverse with a significant focus on vaccines, public health programs, medical, nursing and dental recruitment, immunisation programs and private business health activities. Underpinned by a passion for public health Jane’s experience and skills drive robust strategy development and implementation in preventative health sectors.
Collaboration with all levels of Government Health Personnel (Commonwealth, State and Local) is Jane’s strength for building partnerships and developing solutions based on the needs of the day and the future. Sales and marketing experience supports all aspects of business development and integration with the Australian business sector and government.
Planning, developing and implementing health related programs, specifically immunisation related, at a national and local level is a strength from previous establishment and participation. Consolidating this with current involvement in the immunisation program implementation in the corporate, school, state and local government environment offers up to date facts and experience for new program development.
Claire Tobin Mercier
Claire Tobin Mercier established Claitom Consulting SARL in 2012 to fill the gap existing between AngloSaxon medical diagnostic and medical device companies and the French market. Claire has over 20 years business experience in the European market, primarily in France, as Claire created the French subsidiary of an Irish medical diagnostics company and managed that business from 1994-2009. With responsibility for sales, marketing, human resources and financial reporting, Claire brought the business to market leadership position in a highly competitive market.
In 2010-2011 Claire worked as an independent consultant based in Ireland and had contracts with EKF Diagnostics,Cardiff ; Trinity Biotech, Dublin and Qualigen Inc, USA. On moving back to France in 2012, she continued offering her consulting services with the creation of Claitom Consulting and has built up experience and knowledge of the following therapeutic areas : diagnostics in virology ; parasitology ; biomarkers in transplantation ; Point of Care diagnostics in diabetes and also the treatment of urinary incontinence globally. Development of commercial strategic plans for the introduction of these devices and diagnostics along with market studies are typically the type of contracts which I work on. The following companies have been or continue to be clients of mine : Trinity Biotech Ltd, Ireland ; EKF Diagnostics Ltd, UK ; Analytica Medical Ltd, AUS ; Qualigen Inc, USA ; MM France, Enterprise Ireland, France ; Biomedical Research (BMR) , Ireland and Novartis Pharma, France.
Isabelle Delannoy holds a Doctorate in Veterinary medicine and a Master degree of Management from the Business School of Paris.
The value of vaccines in the prevention of infectious diseases is her primary center of interest with an expertise in Immunology and Vaccinology as well as biological manufacturing, regulatory and industrial stakes.
Isabelle Delannoy holds 30 years of experience in a variety of positions in the Human and Animal Health Pharmaceutical industry.
She has worked 12 years at Sanofi Pasteur in various Franchise positions at a global level or within international Business Units and 18 years in the Animal Health Pharmaceutical Industry (Merial, Schering-Plough, Boehringer Ingelheim).
She has led the development and implementation of global product strategies: the definition of priorities for Research & Development, Industrial Operations, Business Units, and management of specific taskforces to optimize profitability, global forecast assessment of blockbusters as well as Business Development Opportunities.
From 2007 to 2014, she worked as a Senior Director of Flavivirus Vaccines at Sanofi Pasteur, where she led transversal projects in cross-cultural environments, managed relationships with key stakeholders, Yellow fever WHO relationships & advocacy groups. She coordinated medical, marketing, pharmaco-economic, Business Intelligence Public Policy and Communication pre-launch activities for the Dengue vaccine.
She led the Dengue Vaccine Target Product Profile and drove the global forecast assessment with key countries and Business Operations, with a specific focus on Dengue Vaccine Programmatic feasibility
From 2015 to 2017, she was the Head of Pet Vaccines at Merial/ Boehringer Ingelheim Animal Health.